BioSpace News Archive

AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company’s financial results for the quarter ended March 31, 2023.

Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results.

Belite Bio, Inc today announced it will host a virtual Key Opinion Leader event on focusing on adolescent patients with Stargardt disease (STGD1) on Wednesday, May 10, 2023 at 1:00 PM Eastern Time.

SNIPR Biome ApS (“SNIPR”) announces today that Nature Biotechnology has published research findings from its preclinical work on SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, in the human gastrointestinal tract.

BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company announced the opening of its development and clinical service laboratory in Sydney.

Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy to be held in Los Angeles May 16-20, 2023.

Specialty cancer diagnostics company Precipio, Inc. announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services.

Moderna, Inc. (NASDAQ: MRNA) today announced a long-term agreement with Ontario-based Novocol Pharma, a leading sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada.

Galera Therapeutics, Inc. announced that on May 1, 2023, the Compensation Committee of Galera’s board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 315,000 shares of its common stock to three new employees.

Ventyx Biosciences, Inc. announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023.